Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences
March 21 2018 - 7:00AM
Capricor Therapeutics (NASDAQ:CAPR) today announced that it will
participate in two upcoming investment banking conferences,
Oppenheimer’s 28th Annual Healthcare Conference and the Needham
& Company 17th Annual Healthcare Conference in New York City.
Linda Marbán, Ph.D., president and CEO, will present a corporate
overview at both conferences.
Oppenheimer 28th Annual Healthcare
Conference
Date of presentation: Wednesday, March 21, 2018
Time: 9:45 a.m. ET – 10:15 a.m. ET
17th Annual Needham & Company Healthcare
Conference
Date of presentation: Wednesday, March 28, 2018
Time: 4:30 p.m. – 5:00 p.m. ET
To view the presentations via webcast, please
visit: http://capricor.com/news/events/. The
webcasts will be archived for approximately 30 days.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a
clinical-stage biotechnology company focused on the discovery,
development and commercialization of first-in-class biological
therapeutics for the treatment of rare disorders. Capricor’s lead
candidate, CAP-1002, is an allogeneic biologic that is currently in
clinical development for the treatment of Duchenne muscular
dystrophy. Capricor has also established itself as one of the
leading companies investigating the field of extracellular vesicles
and is exploring the potential of CAP-2003, a cell-free,
exosome-based candidate, to treat a variety of disorders. For more
information, visit www.capricor.com.
Keep up with Capricor on social media:
www.facebook.com/capricortherapeutics;
www.instagram.com/capricortherapeutics/ and
https://twitter.com/capricor
Cautionary Note Regarding Forward-Looking
Statements
Statements in this press release regarding the
efficacy, safety, and intended utilization of Capricor's product
candidates; the initiation, conduct, size, timing and results of
discovery efforts and clinical trials; the pace of enrollment of
clinical trials; plans regarding regulatory filings, future
research and clinical trials; regulatory developments involving
products, including the ability to obtain regulatory approvals or
otherwise bring products to market; plans regarding current and
future collaborative activities and the ownership of commercial
rights; scope, duration, validity and enforceability of
intellectual property rights; future royalty streams, expectations
with respect to the expected use of proceeds from the recently
completed offerings and the anticipated effects of the offerings,
and any other statements about Capricor's management team's future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not statements of historical fact (including statements containing
the words "believes," "plans," "could," "anticipates," "expects,"
"estimates," "should," "target," "will," "would" and similar
expressions) should also be considered to be forward-looking
statements. There are a number of important factors that could
cause actual results or events to differ materially from those
indicated by such forward-looking statements. More information
about these and other risks that may impact Capricor's business is
set forth in Capricor's Annual Report on Form 10-K for the year
ended December 31, 2016 as filed with the Securities and Exchange
Commission on March 16, 2017, in its Registration Statement on Form
S-3, as filed with the Securities and Exchange Commission on
September 28, 2015, together with the prospectus included therein
and prospectus supplements thereto, and in its Quarterly Report on
Form 10-Q for the quarter ended September 30, 2017, as filed with
the Securities and Exchange Commission on November 14, 2017. All
forward-looking statements in this press release are based on
information available to Capricor as of the date hereof, and
Capricor assumes no obligation to update these forward-looking
statements.
CAP-1002 is an Investigational New Drug and is
not approved for any indications. CAP-2003 has not yet been
approved for clinical investigation.
For more information, please contact:
AJ Bergmann, Chief Financial Officer
+1-310-358-3200
abergmann@capricor.com
Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From Sep 2023 to Sep 2024